Acar, O.; Agaoglu, A.B.; Sahbazlar, M.; Ekinci, F.; Erdogan, A.P.
Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study. J. Clin. Med. 2025, 14, 7287.
https://doi.org/10.3390/jcm14207287
AMA Style
Acar O, Agaoglu AB, Sahbazlar M, Ekinci F, Erdogan AP.
Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study. Journal of Clinical Medicine. 2025; 14(20):7287.
https://doi.org/10.3390/jcm14207287
Chicago/Turabian Style
Acar, Omer, Ahmet Burak Agaoglu, Mustafa Sahbazlar, Ferhat Ekinci, and Atike Pınar Erdogan.
2025. "Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study" Journal of Clinical Medicine 14, no. 20: 7287.
https://doi.org/10.3390/jcm14207287
APA Style
Acar, O., Agaoglu, A. B., Sahbazlar, M., Ekinci, F., & Erdogan, A. P.
(2025). Survival Benefit of Temozolomide Plus Irinotecan as Second-Line Therapy in Small Cell Lung Cancer: A Retrospective Single-Center Study. Journal of Clinical Medicine, 14(20), 7287.
https://doi.org/10.3390/jcm14207287